| Thursday, October 9th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:45-09:00 | Welcome Coffee | ||
| 09:00-12:00 | IACH 1: Transplant Workshop | ||
| Moderators: TBA | |||
| 09:00-09:30 | Tailoring the intensity of conditioning: TBA | ||
| 09:30-10:00 | Long-term complications of allo-HSCT: TBA | ||
| 10:00-10:30 | VOD after HSCT: 15 years of progress: TBA | ||
| 10:30-10:45 | Short break | ||
| 10:45-11:15 | Chronic GVHD: from steroids to Rock inhibitors: TBA | ||
| 11:15-12:00 | Real-life clinical cases discussion: All workshop faculty |
11:30-12:00 | Industry-supported MTE Session |
| 12:00-12:55 | Lunch Break | ||
| 12:55-14:25 | Transplant 1: HLA and Donor Selection | 12:55-14:25 | MPNCo&D 1: Essential Thrombocytosis in 2025: Updates and New Directions |
| Moderators: TBA | Moderators: Claire Harrison, UK; Naveen Pemmaraju, USA; Ruben Mesa, USA | ||
| 12:55-13:15 | Graft composition of PBSC: TBA | 12:55-13:05 | Opening Remarks by the MPNCo&D co-Chairs |
| 13:15-13:35 | CB expansion: TBA | 13:05-13:20 | Management of patients with ET in 2025 – state-of-the-art for standard of care: Anna Godfrey, UK |
| 13:25-13:55 | HLA: TBA | 13:20-13:35 | Future directions and clinical trial approaches in ET: Claire Harrison, UK |
| 13:55-14:15 | Algorithm for donor selection: TBA | 13:35-13:50 | CALR – Role in pathogenesis and treatment target? Shannon Elf, USA |
| 14:15-14:25 | Panel discussion: All session faculty | 13:50-14:05 | AI and spatial modeling in MPNs: current and future directions: Daniel Royston, UK |
| 14:05-14:25 | Panel discussion: All session faculty | ||
| 14:25-14:35 | Technical Break | ||
| 14:35-16:05 | Transplant 2: Management of relapse of AML and ALL after alloHCT | 14:35-16:05 | MPNCo&D 2: Pre-Fibrotic MF and Myelofibrosis |
| Moderators: TBA | Moderators: Ruben Mesa, USA; Francesco Passamonti, Italy | ||
| 14:35-14:55 | Biology of leukemia relapse: TBA | 14:35-14:50 | A review of pre-fibrotic MF: updates in 2025: Florian Heidel, Germany |
| 14:55-15:15 | Treatment of relapse: TBA | 14:50-15:05 | State-of-the-art treatment of MF – standard of care options: focus on available JAK inhibitors: Ruben Mesa, USA |
| 15:15-15:35 | Application of DLI: TBA | 15:05-15:20 | Anemia in MF – management and treatment options: current and future: Francesco Passamonti, Italy |
| 15:35-15:55 | Relapse after CAR-T in ALL: TBA | 15:20-15:35 | Novel therapies and future clinicial approaches for MF: John Mascarenhas, USA |
| 15:55-16:05 | Panel discussion: All session faculty | 15:35-16:05 | Panel discussion: All session faculty |
| 16:05-16:15 | Coffee Break | ||
| 16:15-17:45 | COLYM 1: General Session | 16:15-17:45 | MPNCo&D 3: Polcythemia Vera and CHIP/Inflammation in MPNs |
| Moderators: Stefano Luminari, Italy; Anna Sureda, Spain | Moderators: Mary Frances McMullin, UK; Adam Mead, UK | ||
| 16:15-16:20 | Case report | 16:15-16:30 | PV in 2025: state-of-the-art and standard of care: Adam Mead, UK |
| 16:20-16:30 | Discussion | ||
| 16:30-16:50 | Contribution of genomic to the diagnosis of lymphomas: Björn Chapuy, Germany |
16:30-16:45 | Novel therapies in PV – clinical trials: Susanne Isfort, Germany |
| 16:50-17:10 | Innovation in the prognostic assessment of lymphoma patients: Naren Epperla, USA |
16:45-17:00 | Reflections on molecular discoveries in enythrocytosis: Mary Frances McMullin, UK |
| 17:10-17:30 | Infections and lymphomas: lessions for the clinicians: Luca Arcaini, Italy |
17:00-17:15 | Inflammation states in MPN – lessons from MDS: Shahram Kordasti, UK |
| 17:30-17:45 | Panel discussion: All session faculty | 17:15-17:45 | Panel discussion: All session faculty |
| 17:45-19:15 | COLYM 2: Indolent Lymphomas | 17:45-19:15 | IACH 2: Progress in the management of GVHD |
| Moderators: Stefano Luminari, Italy; Jessica Okosun, UK | Moderators: TBA | ||
| 17:45-17:50 | Case report | 17:45-18:15 | Update on the biology of chronic GVHD: TBA |
| 17:50-18:00 | Discussion | 18:15-19:00 | Real-life clinical cases discussion: All session faculty |
| 18:00-18:20 | Transformation in indolent lymphomas: identification, prediction and management: Jessica Okosun, UK |
||
| 18:20-18:40 | Follicular lymphomas: impact of novel therapies on the treatment algorithm: Julio Chavez, USA |
||
| 18:40-19:00 | Marginal zone lymphomas: current and future approaches to advanced-stage patients: Côme Bommier, France |
||
| 19:00-19:15 | Panel discussion: All session faculty | ||
| Friday, October 10th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:00-08:15 | Welcome Coffee | ||
| 08:15-09:45 | Transplant 3: ALL Management | 08:15-09:45 | MPNCo&D 4: Immunotherapy, SCT, Novel Approaches in MPNs |
| Moderators: TBA | Moderators: Anna Godfrey, UK; Susanne Isfort, Germany | ||
| 08:15-08:35 | AlloHCT in ALL: TBA | 08:15-08:30 | Novel clinical approaches targeting CALR – translational/clinical approaches: Bethan Psaila, UK |
| 08:35-08:55 | Maintenance in ALL after alloHCT: | 08:30-09:00 | Should blastic phase MPN be aggressively treated? Yes: Tania Jain, USA No: Bart Scott, USA |
| 08:55-09:15 | CAR-T cell in T-ALL: TBA | 09:00-09:15 | Recent data to achieve the best from allografting in MF: Donal McLornan, UK |
| 09:15-09:35 | CAR-T in B-ALL ped and adults: TBA | 09:15-09:45 | Panel discussion: All session faculty |
| 09:35-09:45 | Panel discussion: All session facultyaaa | ||
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:30 | Industry-supported Morning Symposium | 10:00-11:30 | CME Morning Symposium |
| 11:30-11:40 | Technical Break | ||
| 11:40-13:10 | Transplant 4: AML Management | 11:40-13:10 | MPNCo&D 5: Spotlight on Rare MPNs: Not as Rare As You Think |
| Moderators: TBA | Moderators: Deepti Radia, UK; Andreas Reiter, Germany | ||
| 11:40-12:00 | Predictive score for AML: TBA | 11:40-11:55 | CMML – updates and future directions: Daniel Wiseman, UK |
| 12:00-12:20 | Conditioning regimen in AML: TBA | 11:55-12:10 | Hypereosinophilic syndromes in 2025: Andreas Reiter, Germany |
| 12:20-12:40 | Maintenance in AML: TBA | 12:10-12:25 | Systemic mastocytosis: Deepti Radia, UK |
| 12:40-13:00 | CAR-T construct for AML: TBA | 12:25-12:40 | Focus on rare hematologic malignancies: pearls and reflections: Naveen Pemmaraju, USA |
| 13:00-13:10 | Panel discussion: All session faculty | 12:40-13:10 | Panel discussion: All session faculty |
| 13:10-13:40 | Lunch Break | ||
| 13:40-15:10 | Industry-supported Lunch Symposium | 13:40-15:10 | Industry-supported Lunch Symposium |
| 15:10-15:20 | Technical Break | ||
| 15:20-16:50 | COLYM 3: Chronic Lymphocytic Leukemia | 15:20-16:50 | COMydAL 1: MDS I |
| Moderators: Mohamed Kharfan-Dabaja, USA; Stefano Luminari, Italy | Moderators: TBA | ||
| 15:20-15:25 | Case report | 15:20-15:35 | An update on IDH inhibitors in MDS: Lionel Adès, France |
| 15:25-15:35 | Discussion | ||
| 15:35-15:55 | Time-limited vs continuous therapy as front-line treatment of CLL: matching the bset approach to the right patient: Talha Munir, UK |
15:35-15:50 | An update on AZA-based combinations in MDS: Astrid Olsnes, Norway |
| 15:55-16:15 | Treatment of relapsed and/or refractory CLL after failure of a covalent BTK and BCL2 inhibitors: Farrukh Awan, USA |
15:50-16:05 | An update on immune biomarkers and targeting in MDS: Shahram Kordasti, UK |
| 16:15-16:35 | BTK degraders: what are they and how will they shape CLL management? TBA | 16:05-16:20 | An update on response and MRD assessment in MDS: Arjan van Loosdrecht, Netherlands |
| 16:35-16:50 | Panel discussion: All session faculty | 16:20-16:50 | Panel discussion: All session faculty |
| 16:50-17:00 | Coffee Break | ||
| 17:00-18:30 | COLYM 4: Hodgkin Lymphoma | 17:00-18:30 | COMydAL 2: AML I |
| Moderators: Andrew Evens, USA; Anna Sureda, Spain | Moderators: TBA | ||
| 17:00-17:05 | Case report | 17:00-17:15 | Should FLT3 inhibitors be a frontline therapy for older FLT3-mut AML: TBA |
| 17:05-17:15 | Discussion | ||
| 17:15-17:35 | Divide across the pond: how to select between N-AVD or BrECADD in newly diagnosed cHL? Justin Ferdinandus, Germany |
17:15-17:30 | AZA-VEN vs AZA-IVO for frontline therapy of older IDH1 mutated AML? Ume Borate, USA |
| 17:35-17:55 | Harnessing predictive modelling for individualized therapy in Hodgkin Lymphoma: Andrew Evens, USA |
17:30-17:45 | How should we stratify AML in 2025: Thomas Cluzeau, France |
| 17:55-18:15 | Do all relapsed cHL need an autologous treatment as consolidation? Christine Mauz-Körholz, Germany |
17:45-18:00 | An update on menin inhibitors in AML patients: Amer Zeidan, USA |
| 18:15-18:30 | Panel discussion: All session faculty | 18:00-18:30 | Panel discussion: All session faculty |
| 18:30-19:00 | IACH 3: Awards | ||
| Saturday, October 11th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:00-08:15 | Welcome Coffee | ||
| 08:15-09:45 | Transplant 5: GVHD | 08:15-09:45 | IACH 4: Updates in the management of multiple myeloma |
| Moderators: TBA | Moderators: TBA | ||
| 08:15-08:35 | Biomarkers of GVHD for an individualized prophylaxis: TBA | 08:15-08:45 | Transplant of eligible patients: TBA |
| 08:35-08:55 | PTCy tolerance and long-term effect: TBA | 08:45-09:15 | Non-transplant eligible patients: TBA |
| 08:55-09:15 | New treatment for aGVHD: TBA | 09:15-09:45 | Management of relapse: TBA |
| 09:15-09:35 | Management of cGVHD: TBA | ||
| 09:35-09:45 | Panel discussion: All session faculty | ||
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:00 | Industry-supported Symposium | 10:00-11:00 | Industry-supported Symposium |
| 11:00-11:10 | Technical Break | ||
| 11:10-12:40 | COLYM 5: Aggressive B-Cell Lymphoma | 11:10-12:40 | COMydAL 3: MDS/MPN |
| Moderators: Anna Sureda, Spain; Mohamed Kharfan-Dabaja, USA | Moderators: Lisa Pleyer, Austria & TBA | ||
| 11:10-11:15 | Case report | 11:10-11:25 | Defining MDS/MPN entities for clinical decision making: Daniel Wiseman, UK |
| 11:15-11:25 | Discussion | ||
| 11:25-11:45 | “All comers” vs “molecularly driven” treatment strategies in first-line DLBCL patients: where are we heading to? Umberto Vitolo, Italy |
11:25-11:40 | Molecular classification along the myeloid neoplasm spectrum: Matteo Della Porta, Italy |
| 11:45-12:05 | Changing the field in RR DLBCL: CAR-T cells and BiEsp MoAb: TBA | 11:40-11:55 | CMML molecular landscape: Laura Palomo, Spain |
| 12:05-12:25 | Is there life after CAR-T? Mechanisms of resistance and potential therapeutic strategies: Roni Shouval, USA |
11:55-12:10 | MDS/MPN – an update on therapeutics: Francesco Onida, Italy |
| 12:25-12:40 | Panel discussion: All session faculty | 12:10-12:40 | Panel discussion: All session faculty |
| 12:40-13:10 | Lunch Break | ||
| 13:10-14:40 | COLYM 6: Mantle Cell Lymphoma | 13:10-14:40 | COMydAL 4: MDS II |
| Moderators: Marco Ladetto, Italy; Anna Sureda, Spain; TBA | Moderators: Sophie Park, France & TBA | ||
| 13:10-13:15 | Case report | 13:10-13:25 | Dissecting biology of MDS Del5q: Julia Montoro, Spain |
| 13:15-13:25 | Discussion | ||
| 13:25-13:45 | Should we abandon auto-HCT as first-line consolidation therapy in de novo MCL patients? Olivier Hermine, France |
13:25-13:40 | Should we improve selection of patients for ESA therapy? Marco Raddi, Italy |
| 13:45-14:05 | Choosing between a BTK inhibitor and CAR-T cell therapy in RR MCL: Marco Ladetto, Italy |
13:40-13:55 | Autoimmunity in MDS: Lin Pierre Zhao, France |
| 14:05-14:25 | Management of relapsed TP53 mutated mantle cell lymphoma: is allogeneic HCT still a major player? Nora Liebers, Germany |
13:55-14:10 | Evolving therapeutic algorithm for LR MDS: ESA, luspatercept, imetelstat: Valeria Santini, Italy |
| 14:25-14:40 | Panel discussion: All session faculty | 14:10-14:40 | Panel discussion: All session faculty |
| 14:40-16:00 | IACH 5: Advances in CAR-T cells | 14:40-16:00 | COMydAL 5: AML II |
| Moderators: TBA | Moderators: TBA | ||
| 14:40-15:10 | Plenary lecture: Next generation CAR-T cells: TBA | 14:40-14:55 | Are retinoids out of fasion in non-APL AML/HR-MDS? Amy deZern, USA |
| 15:10-15:35 | TBA | 14:55-15:10 | An update on TP53 AML biology and targeting in AML/HR-MDS: Max Stahl, Germany |
| 15:35-16:00 | TBA | 15:10-15:25 | Germline predisposition in AML and MDS: Marie Sebert, France |
| 15:25-15:40 | The role of inflammation in AML and MDS: Antonio Curti, Italy |
||
| 15:40-16:00 | Panel discussion: All session faculty | ||
| 16:00-16:15 | Closing Remarks | ||